Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON: Cetuximab-IRDye800CW in HNSCC Surgery
NCT03134846Phase 2Unknown
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab-IRDye 800CW in head and neck squamous cell carcinoma (HNSCC), sponsored by University Medical Center Groningen. Status: unknown.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03134846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03134846.